Applying these driver proportions to overall intestinal tumour counts revealed that, for example, KrasG12D priming resulted in 596-fold and 58-fold increases in the number of Ctnnb1- and Apc-driven tumours, respectively, relative to the control cohort (Fig. 1j,k). Here, CTNNB1 is linked to neoplasm.